A living WHO guideline on drugs to prevent covid-19.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lamontagne François, Stegemann Miriam, Agarwal Arnav, Agoritsas Thomas, Siemieniuk Reed, Rochwerg Bram, Bartoszko Jessica, Askie Lisa, Macdonald Helen, Al-Maslamani Muna, Amin Wagdy, Da Silva Andre Ricardo Araujo, Barragan Fabian Alberto Jaimes, Bausch Frederique Jacquerioz, Burhan Erlina, Cecconi Maurizio, Chacko Binila, Chanda Duncan, Dat Vu Quoc, Du Bin, Geduld Heike, Gee Patrick, Haider Muhammad, Nerina Harley, Hashimi Madiha, Jehan Fyezah, Hui David, Hunt Beverley J, Ismail Mohamed, Kabra Sushil, Kanda Seema, Kawano-Dourado Leticia, Kim Yae-Jean, Kissoon Niranjan, Krishna Sanjeev, Kwizera Arthur, Lisboa Thiago, Leo Yee-Sin, Mahaka Imelda, Hela Manai, Migliori Giovanni Battista, Mino Greta, Nsutebu Emmanuel, Pshenichnaya Natalia, Qadir Nida, Ranganathan Shalini Sri, Sabzwari Saniya, Sarin Rohit, Shankar-Hari Manu, Sharland Michael, Shen Yinzhong, Souza Joao Paulo, Tshokey Tshokey, Ugarte Sebastian, Uyeki Tim, Venkatapuram Sridhar, Wachinou Ablo Prudence, Wijewickrama Ananda, Vuyiseka Dubula, Preller Jacobus, Brignardello-Petersen Romina, Kum Elena, Qasim Anila, Zeraatkar Dena, Owen Andrew, Guyatt Gordon, Lytvyn Lyubov, Jacobs Michael, Vandvik Per Olav, Diaz Janet
Аннотация
RECOMMENDATION: The guideline development panel made a strong recommendation against the use of hydroxychloroquine for individuals who do not have covid-19 (high certainty).
HOW THIS GUIDELINE WAS CREATED: This living guideline is from the World Health Organization (WHO) and provides up to date covid-19 guidance to inform policy and practice worldwide. Magic Evidence Ecosystem Foundation (MAGIC) provided methodological support. A living systematic review with network analysis informed the recommendations. An international guideline development panel of content experts, clinicians, patients, an ethicist and methodologists produced recommendations following standards for trustworthy guideline development using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.
UNDERSTANDING THE NEW RECOMMENDATION: The linked systematic review and network meta-analysis (6 trials and 6059 participants) found that hydroxychloroquine had a small or no effect on mortality and admission to hospital (high certainty evidence). There was a small or no effect on laboratory confirmed SARS-CoV-2 infection (moderate certainty evidence) but probably increased adverse events leading to discontinuation (moderate certainty evidence). The panel judged that almost all people would not consider this drug worthwhile. In addition, the panel decided that contextual factors such as resources, feasibility, acceptability, and equity for countries and healthcare systems were unlikely to alter the recommendation. The panel considers that this drug is no longer a research priority and that resources should rather be oriented to evaluate other more promising drugs to prevent covid-19.
UPDATES: This is a living guideline. New recommendations will be published in this article and signposted by update notices to this guideline.
READERS NOTE: This is the first version of the living guideline for drugs to prevent covid-19. It complements the WHO living guideline on drugs to treat covid-19. When citing this article, please consider adding the update number and date of access for clarity.